OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Commerce. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
November 27, 2023
AbbVie and Genmab will share commercial responsibilities in the United States and Japan for epcoritamab-bysp (Epkinly) for the treatment of adults with follicular lymphoma that is relapsed or refractory following treatment with two or more therapies.
Alladapt Immunotherapeutics said the FDA Fast Track designation highlights the importance of developing a treatment for multiple food allergens.
November 20, 2023
Webinar Date/Time: Thu, Dec 14, 2023 11:00 AM EST
November 17, 2023
The FDA also approved a companion diagnostic test to detect the PIK3CA, AKT1, and PTEN alterations as part of the approval for AstraZeneca’s capivasertib (Truqap) plus fulvestrant (Faslodex) for HR-positive, HER2-negative locally advanced or metastatic breast cancer.
Enzalutamide (Xtandi) gets FDA approval to treat nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
With new mandates right around the corner, there is an unwavering demand for pharma operations to perform at peak efficiency.
Pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction cancer approved by FDA after being found to lower the risk of metastasis or death.
November 16, 2023
Bristol Myers Squibb’s repotrectinib (Augtyro) approved by FDA to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer.
November 15, 2023
Patients with kidney failure administered chronic hemodialysis who received DefenCath showed a statistically significant lower incidence of catheter-related bloodstream infections.
November 13, 2023
Exparel was initially approved in 2011 for single-dose infiltration into a surgical site.